Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
PublisherOxford University Press
MetadataShow full item record
AbstractBACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) jeopardizes global TB control. The prevalence and predictors of Rifampicin-resistant (RR) TB, a proxy for MDR-TB, and the treatment outcomes with standard and shortened regimens have not been assessed in post-conflict regions, such as the South Kivu province in the eastern Democratic Republic of the Congo (DRC). We aimed to fill this knowledge gap and to inform the DRC National TB Program. METHODS: of adults and children evaluated for pulmonary TB by sputum smear microscopy and Xpert MTB/RIF (Xpert) from February 2012 to June 2017. Multivariable logistic regression, Kaplan-Meier estimates, and multivariable Cox regression were used to assess independent predictors of RR-TB and treatment failure/death. RESULTS: Of 1535 patients Xpert-positive for TB, 11% had RR-TB. Independent predictors of RR-TB were a positive sputum smear (adjusted odds ratio [aOR] 2.42, 95% confidence interval [CI] 1.63-3.59), retreatment of TB (aOR 4.92, 95% CI 2.31-10.45), and one or more prior TB episodes (aOR 1.77 per episode, 95% CI 1.01-3.10). Over 45% of RR-TB patients had no prior TB history or treatment. The median time from Xpert diagnosis to RR-TB treatment initiation was 12 days (interquartile range 3-60.2). Cures were achieved in 30/36 (83%) and 84/114 (74%) of patients on 9- vs 20/24-month MDR-TB regimens, respectively (P = .06). Predictors of treatment failure/death were the absence of directly observed therapy (DOT; adjusted hazard ratio [aHR] 2.77, 95% CI 1.2-6.66) and any serious adverse drug event (aHR 4.28, 95% CI 1.88-9.71). CONCLUSIONS: Favorable RR-TB cure rates are achievable in this post-conflict setting with a high RR-TB prevalence. An expanded Xpert scale-up; the prompt initiation of shorter, safer, highly effective MDR-TB regimens; and treatment adherence support are critically needed to optimize outcomes. Copyright The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Identifier to cite or link to this itemhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85072704103&doi=10.1093%2fcid%2fciy1105&partnerID=40&md5=9c08700fb6a6339fbaf7d79e9ae870c1; http://hdl.handle.net/10713/11055
- Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey.
- Authors: Iem V, Dean A, Zignol M, Vongvichit P, Inthavong D, Siphanthong S, Sorsavanh T, Kim SJ, Shin S, Sébert J, Chittamany P
- Issue date: 2019 Apr
- Active case finding of rifampicin sensitive and resistant TB among household contacts of drug resistant TB patients in Andhra Pradesh and Telangana states of India - A systematic screening intervention.
- Authors: Chatla C, Jaju J, Achanta S, Samyuktha R, Chakramahanti S, Purad C, Chepuri R, Nair SA, Parmar M
- Issue date: 2018 Jul
- Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
- Authors: Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N
- Issue date: 2014 Jan 21
- Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study.
- Authors: van Kampen SC, Tursynbayeva A, Koptleuova A, Murzakhmetova Z, Bigalieva L, Aubakirova M, Pak S, van den Hof S
- Issue date: 2015
- Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China.
- Authors: Wu Z, Rueda ZV, Li T, Zhang Z, Jiang Y, Sha W, Yu F, Chen J, Pan Q, Shen X, Yuan Z
- Issue date: 2020 Feb 18